Related Experiment Videos
[Clinical studies on cefixime in pediatrics]
Insights
Cefixime (CFIX), an oral cephalosporin antibiotic, demonstrated significant clinical utility in pediatric patients. This new antibiotic achieved an 87.4% overall efficacy rate in treating various bacterial infections in children.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Bacterial infections pose a significant health challenge in pediatric populations.
- The need for effective and safe oral antibiotics in children is paramount.
- Cephalosporins are a widely used class of antibiotics, and new agents are continually evaluated.
Purpose of the Study:
- To investigate the clinical usefulness of cefixime (CFIX), a novel oral cephalosporin, in pediatric patients.
- To assess the efficacy and safety of CFIX in treating common pediatric bacterial infections.
- To evaluate the bacteriological eradication rates of CFIX against common pathogens.
Main Methods:
- A clinical study involving 138 pediatric patients with various bacterial infections.
- Infections included upper respiratory tract infections (RTI), acute bronchitis, pneumonia, scarlet fever, and urinary tract infections (UTI).
- Bacteriological eradication and side effect profiles were assessed.
Main Results:
- CFIX demonstrated an overall clinical efficacy rate of 87.4% across all infection types.
- High efficacy rates were observed in upper RTI (85.7%), acute bronchitis (89.5%), pneumonia (94.4%), and UTI (90.5%).
- A bacteriological eradication rate of 86.0% was achieved, with 100% eradication of Haemophilus influenzae and parainfluenzae.
Conclusions:
- Cefixime (CFIX) is a highly effective and well-tolerated oral cephalosporin for treating bacterial infections in children.
- The favorable efficacy and safety profile suggest CFIX as a valuable therapeutic option for pediatric infectious diseases.
- Further research may explore CFIX's role in specific pediatric populations and against a broader spectrum of pathogens.
Abstract:
Clinical usefulness of cefixime (CFIX), a new oral cephalosporin antibiotic, in pediatric field was investigated. The results obtained were summarized as follows. 1. The clinical efficacy of CFIX was investigated in a total of 138 children including 49 with upper respiratory tract infections (RTI), 22 with acute bronchitis, 18 with pneumonia, 19 with scarlet fever and 21 with urinary tract infections (UTI). 2. Clinical effectiveness was excellent in 58, good in 60, fair in 14 and poor in 3, with an overall efficacy rate of 87.4%. The efficacy rate classified according to types of infection were 85.7% in upper RTI, 89.5% in acute bronchitis, 94.4% in pneumonia, 78.9% in scarlet fever, and 90.5% in UTI. 3. Out of the suspected causative organisms, 43 strains of a total of 50 strains isolated were eradicated. The bacteriological eradication rate was 86.0%. (Haemophilus influenzae 100%, Haemophilus parainfluenzae 100%, Streptococcus pyogenes 88.5%, Escherichia coli 85.7%). 4. One hundred forty four children were analyzed for side effect. Side effects were observed in 2 children (1.4%) with diarrhea in 1 and anorexia in another. Abnormal laboratory test results were recorded in 4 children (3.3%). The above results suggest that CFIX is a very useful new oral cephalosporin for the treatment of bacterial infections in children.